↧
Image may be NSFW.
Clik here to view.
Clik here to view.
Rodman starts Evoke Pharma at buy
Rodman & Renshaw has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “buy” rating and $27 price target. The stock closed at $2.91 on Wednesday. Evoke is currently focused on advancing an...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Titan Pharma advancing pipeline in PD, other disorders
Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...
View Article